Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-8: Durvalumab Plus Domvanalimab in Unresectable Stage III NSCLC
NCT05211895Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2022
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Arm A: Durvalumab + Domvanalimab with Arm B: Durvalumab + Placebo (2 arms). Primary endpoint: Progression-Free Survival at 5 years. Started Feb 2022; status: active, not recruiting.
02
Drugs
domvanalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05211895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05211895.